Hansa Biopharma Unveils Promising Findings on Imlifidase for Guillain-Barré Syndrome at 2025 PNS Annual Meeting At the 2025 PNS Annual Meeting in Edinburgh, Hansa Biopharma reveals groundbreaking data on imlifidase's effectiveness for Guillain-Barré Syndrome treatment, showcasing its potential.

Hansa Biopharma Unveils Promising Findings on Imlifidase for Guillain-Barré Syndrome at 2025 PNS Annual Meeting #Sweden #Lund #Hansa_Biopharma #imlifidase #GBS_Treatment